OCT | 2017
FOUNDATION LAUNCHES FOX INSIGHT TO AMPLIFY PATIENT VOICE IN RESEARCH
In collaboration with personal genetics company 23andMe , MJFF announces Fox Insight ( foxinsight . org ), an online clinical study building a large , diverse research cohort of Parkinson ’ s patients and control volunteers . The study ’ s goal is to provide researchers , drug makers , regulators and payers critical insight into the lived experience , genetics and variability of Parkinson ’ s disease . The study is open to anyone 18 or older worldwide with or without Parkinson ’ s disease and aims to recruit tens or even hundreds of thousands of patients to contribute data .
DEC | 2017
LRRK2 TREATMENT ENTERS CLINICAL TESTING
San Francisco biotech Denali Therapeutics announces positive results from its first-in-human LRRK2 clinical trial . The company finds that the experimental treatment is safe , and it lowers LRRK2 protein activity in the blood of volunteers who do not have Parkinson ’ s disease . The company also says that it will soon move into studies in people with Parkinson ’ s carrying a LRRK2 mutation .
17